Al­bireo re­veals $385K price tag for new­ly ap­proved pru­ri­tis drug; Jen­nifer Doud­na's Cari­bou up­sizes IPO

Al­bireo scored a big break­through when it won ap­proval by the FDA and EMA this week for Byl­vay (ode­vix­i­bat), the first drug ap­proved to treat pru­ri­tus in pa­tients suf­fer­ing from all forms of pro­gres­sive fa­mil­ial in­tra­hep­at­ic cholesta­sis. And they wast­ed no time in rolling out a jaw-drop­ping price. In a call with an­a­lysts on Wednes­day, com­pa­ny ex­ecs out­lined a weight-based ap­proach they say will cre­ate an av­er­age per-pa­tient price of $385,000.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.